Viewing Study NCT00189124



Ignite Creation Date: 2024-05-05 @ 11:57 AM
Last Modification Date: 2024-10-26 @ 9:17 AM
Study NCT ID: NCT00189124
Status: COMPLETED
Last Update Posted: 2016-05-18
First Post: 2005-09-13

Brief Title: Dehydroepiandrosterone DHEA in Systemic Lupus Erythematosus SLE for Coronary Artery Disease CAD Prevention
Sponsor: University of Michigan
Organization: University of Michigan

Study Overview

Official Title: Does DHEA Improve Endothelial Dysfunction and Other Cardiovascular Risk Factors in Premenopausal Women With Systemic Lupus
Status: COMPLETED
Status Verified Date: 2016-05
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: No
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: The purpose of this study is to evaluate the effect of DHEA on endothelial dysfunction in patients with systemic lupus by measuring

1 changes in brachial artery flow-mediated dilatation FMD and
2 changes in biomarkers of cardiovascular risk Patients will be enrolled in a randomized double-blinded crossover trial of DHEA or placebo for ten weeks then crossed over to the alternate treatment arm after a six-week washout period

HYPOTHESIS Dehydroepiandrosterone DHEA administration in premenopausal women with SLE modifies cardiovascular risk by improving vascular endothelial function and other biomarkers associated with cardiovascular heart disease
Detailed Description: None

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None